Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis

Current Opinion in Rheumatology

Volumn 24, Issue 5, 2012, Pages 441-450

  Knight, Jason S ^a   Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COMPLEMENT COMPONENT C1Q; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEFENSIN; DOUBLE STRANDED DNA; ELASTASE; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MYCOPHENOLIC ACID; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RIBONUCLEOPROTEIN ANTIBODY; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNITY; AUTOPHAGY; CELL DEATH; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOKINE RELEASE; CYTOTOXICITY; DISEASE ACTIVITY; ENZYME ACTIVITY; GRANULOCYTE; HUMAN; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS NEPHRITIS; NEUTROPHIL; NEUTROPHIL EXTRACELLULAR TRAP; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMALL VESSEL VASCULITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADAPTIVE IMMUNITY; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNITY; CELL DEATH; DENDRITIC CELLS; EXTRACELLULAR SPACE; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; NEUTROPHILS;

EID: 84864881063     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283546703     Document Type: Review

References (114)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110-2121.
2. Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:317-325.
3. Dorner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods 2011; 363:187-197.
4. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25:383-392.
5. Elkon KB, Stone VV. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31:803-812.
6. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:1540-1543.
7. Lee PY, Weinstein JS, Nacionales DC, et al. A novel type I IFN-producing cell subset in murine lupus. J Immunol 2008; 180:5101-5108.
8. Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010; 184:3284-3297.
9. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; the tart cell and the l.E. Cell Proc Staff Meet Mayo Clin 1948; 23:25-28.
10. Kobayashi SD, DeLeo FR. Role of neutrophils in innate immunity: a systems biology-level approach. Wiley Interdiscip Rev Syst Biol Med 2009; 1:309-333.
11. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303:1532-1535.
12. Brandt L, Hedberg H. Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. Scand J Haematol 1969; 6:348-353.
13. Courtney PA, Crockard AD, Williamson K, et al. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded dna, and neutropenia. Ann Rheum Dis 1999; 58:309-314.
14. Hashimoto Y, Ziff M, Hurd ER. Increased endothelial cell adherence, aggregation, and superoxide generation by neutrophils incubated in systemic lupus erythematosus and felty's syndrome sera. Arthritis Rheum 1982; 25:1409-1418.
15. Abramson SB, Given WP, Edelson HS, Weissmann G. Neutrophil aggregation induced by sera from patients with active systemic lupus erythematosus. Arthritis Rheum 1983; 26:630-636.
16. Molad Y, Buyon J, Anderson DC, et al. Intravascular neutrophil activation in systemic lupus erythematosus (sle): dissociation between increased expression of cd11b/cd18 and diminished expression of l-selectin on neutrophils from patients with active sle. Clin Immunol Immunopathol 1994; 71:281-286.
17. Jonsson H, Sturfelt G. A novel assay for neutrophil clustering activity of human sera: relation to disease activity and neutropenia in systemic lupus erythematosus. Ann Rheum Dis 1990; 49:46-50.
18. Hacbarth E, Kajdacsy-Balla A. Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever. Arthritis Rheum 1986; 29:1334-1342.
19. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711-723.
20. Sthoeger ZM, Bezalel S, Chapnik N, et al. High alpha-defensin levels in patients with systemic lupus erythematosus. Immunology 2009; 127:116-122.
21. Vordenbaumen S, Fischer-Betz R, Timm D, et al. Elevated levels of human beta-defensin 2 and human neutrophil peptides in systemic lupus erythematosus. Lupus 2010; 19:1648-1653.
22. Ma CY, Jiao YL, Zhang J, et al. Elevated plasma level of hmgb1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 2012; 32:395-402.
23. Drew SI, Terasaki PI. Autoimmune cytotoxic granulocyte antibodies in normal persons and various diseases. Blood 1978; 52:941-952.
24. Starkebaum G, Arend WP. Neutrophil-binding immunoglobulin g in systemic lupus erythematosus. J Clin Invest 1979; 64:902-912.
25. Hadley AG, Byron MA, Chapel HM, et al. Antigranulocyte opsonic activity in sera from patients with systemic lupus erythematosus. Br J Haematol 1987; 65:61-65.
26. Nassberger L, Jonsson H, Sjoholm AG, et al. Circulating antielastase in systemic lupus erythematosus. Lancet 1989; 1:509.
27. Nassberger L, Sjoholm AG, Jonsson H, et al. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 1990; 81:380-383.
28. Ecklund SR, Saluta GS, Agudelo CA, Pisko EJ. Antineutrophil cytoplasmic antibodies: clinical characteristics of 10 patients with the perinuclear pattern of immunofluorescence on anca testing. South Med J 1992; 85:132-138.
29. Lee SS, Lawton JW, Chan CE, et al. Antilactoferrin antibody in systemic lupus erythematosus. Br J Rheumatol 1992; 31:669-673.
30. Pauzner R, Urowitz M, Gladman D, Gough J. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. J Rheumatol 1994; 21:1670-1673.
31. Cambridge G, Wallace H, Bernstein RM, Leaker B. Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33:109-114.
32. Schnabel A, Csernok E, Isenberg DA, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus: prevalence, specificities, and clinical significance. Arthritis Rheum 1995; 38:633-637.
33. Spronk PE, Bootsma H, Horst G, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996; 35:625-631.
34. Zhao MH, Liu N, Zhang YK, Wang HY. Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in chinese patients with lupus nephritis. Nephrol Dial Transplant 1998; 13:2821-2824.
35. Galeazzi M, Morozzi G, Sebastiani GD, et al. Antineutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European concerted action on the immunogenetics of SLE. Clin Exp Rheumatol 1998; 16:541-546.
36. Chin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol 2000; 20:57-63.
37. Manolova I, Dancheva M, Halacheva K. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol Int 2001; 20:197-204.
38. Molnar K, Kovacs L, Kiss M, et al. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus. Clin Exp Dermatol 2002; 27:59-61.
39. Hsieh SC, Yu HS, Lin WW, et al. Antissb/la is one of the antineutrophil autoantibodies responsible for neutropenia and functional impairment of polymorphonuclear neutrophils in patients with systemic lupus erythematosus. Clin Exp Immunol 2003; 131:506-516.
40. Tang Z, Wu Y, Wang Q, et al. Clinical spectrum of diffuse crescentic glomerulonephritis in Chinese patients. Chin Med J (Engl) 2003; 116: 1737-1740.
41. Fauzi AR, Kong NC, Chua MK, et al. Antibodies in systemic lupus antineutrophil cytoplasmic erythematosus: prevalence, disease activity correlations and organ system associations. Med J Malaysia 2004; 59:372-377.
42. Chen M, Zhao MH, Zhang Y, Wang H. Antineutrophil autoantibodies and their target antigens in systemic lupus erythematosus. Lupus 2004; 13:584-589.
43. Caccavo D, Rigon A, Picardi A, et al. Antilactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. Clin Rheumatol 2005; 24:381-387.
44. Tamiya H, Tani K, Miyata J, et al. Defensins-and cathepsin g-anca in systemic lupus erythematosus. Rheumatol Int 2006; 27:147-152.
45. Biswas D, Mathias A, Dayal R, et al. Presence of antibodies to ssb/la is associated with decreased phagocytic efficiency of neutrophils in patients with systemic lupus erythematosus. Clin Rheumatol 2008; 27:717-722.
46. Pan HF, Fang XH, Wu GC, et al. Antineutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation 2008; 31:260-265.
47. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011; 7:691-699.
48. Cochrane CG, Unanue ER, Dixon FJ. A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis. J Exp Med 1965; 122:99-116.
49. Henson PM. Pathologic mechanisms in neutrophil-mediated injury. Am J Pathol 1972; 68:593-612.
50. Hotta O, Oda T, Taguma Y, et al. Role of neutrophil elastase in the development of renal necrotizing vasculitis. Clin Nephrol 1996; 45:211-216.
51. Johnson RJ, Couser WG, Alpers CE, et al. The human neutrophil serine proteinases, elastase and cathepsin g, can mediate glomerular injury in vivo. J Exp Med 1988; 168:1169-1174.
52. Austin HA 3rd, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25:689-695.
53. Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhoodonset systemic lupus erythematosus disease activity. Arthritis Rheum 2009; 60:2772-2781.
54. Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88: 23-31.
55. Gulati A, Paige D, Yaqoob M, et al. Palisaded neutrophilic granulomatous dermatitis associated with systemic lupus erythematosus presenting with the burning rope sign. J Am Acad Dermatol 2009; 61:711-714.
56. Hospach T, von den Driesch P, Dannecker GE. Acute febrile neutrophilic dermatosis (sweet's syndrome) in childhood and adolescence: two new patients and review of the literature on associated diseases. Eur J Pediatr 2009; 168:1-9.
57. Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010; 19:1050-1070.
58. Lipsker D, Saurat JH. Neutrophilic cutaneous lupus erythematosus. At the edge between innate and acquired immunity? Dermatology 2008; 216:283-286.
59. Amulic B, Hayes G. Neutrophil extracellular traps. Curr Biol 2011; 21:R297-R298.
60. Remijsen Q, Kuijpers TW, Wirawan E, et al. Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ 2011; 18:581-588.
61. Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol 2009; 30:513-521.
62. von Kockritz-Blickwede M, Nizet V. Innate immunity turned inside-out: antimicrobial defense by phagocyte extracellular traps. J Mol Med (Berl) 2009; 87:775-783.
63. Medina E. Neutrophil extracellular traps: a strategic tactic to defeat pathogens with potential consequences for the host. J Innate Immun 2009; 1:176-180.
64. Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2012; 7:e32366.
65. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187:538-552.
66. Gupta AK, Joshi MB, Philippova M, et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to netosis-mediated cell death. FEBS Lett 2010; 584:3193-3197.
67. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13:463-469.
68. Brill A, Fuchs TA, Savchenko A, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2011; 10: 136-144.
69. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107:15880-15885.
70. Remijsen Q, Vanden Berghe T, Wirawan E, et al. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Res 2011; 21:290-304.
71. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007; 176:231-241.
72. Ermert D, Urban CF, Laube B, et al. Mouse neutrophil extracellular traps in microbial infections. J Innate Immun 2009; 1:181-193.
73. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of net formation by gene therapy in CGD controls aspergillosis. Blood 2009; 114:2619-2622.
74. Palmer LJ, Cooper PR, Ling MR, et al. Hypochlorous acid regulates neutrophil extracellular trap release in humans. Clin Exp Immunol 2012; 167:261-268.
75. Nishinaka Y, Arai T, Adachi S, et al. Singlet oxygen is essential for neutrophil extracellular trap formation. Biochem Biophys Res Commun 2011; 413:75-79.
76. Hakkim A, Fuchs TA, Martinez NE, et al. Activation of the RAF-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol 2011; 7:75-77.
77. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in neutrophils. J Immunol 2008; 180:1895-1902.
78. Hemmers S, Teijaro JR, Arandjelovic S, Mowen KA. Pad4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One 2011; 6:e22043.
79. Li P, Li M, Lindberg MR, et al. Pad4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 2010; 207:1853-1862.
80. Wang Y, Li M, Stadler S, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol 2009; 184:205-213.
81. Metzler KD, Fuchs TA, Nauseef WM, et al. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood 2011; 117:953-959.
82. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010; 191:677-691.
83. Mitroulis I, Kambas K, Chrysanthopoulou A, et al. Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout. PLoS One 2011; 6:e29318.
84. Neeli I, Dwivedi N, Khan S, Radic M. Regulation of extracellular chromatin release from neutrophils. J Innate Immun 2009; 1:194-201.
85. Urban CF, Ermert D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against candida albicans. PLoS Pathog 2009; 5:e1000639.
86. Liu CL, Tangsombatvisit S, Rosenberg JM, et al. Specific posttranslational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res Ther 2012; 14: R25.
87. Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012; 188:3522-3531.
88. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type i IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra20.
89. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra19.
90. Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623-625.
91. Chen M, Kallenberg CG. New advances in the pathogenesis of ANCAassociated vasculitides. Clin Exp Rheumatol 2009; 27 (1 Suppl 52):S108-S114.
92. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
93. Pfister H, Ollert M, Frohlich LF, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (wegener autoantigen) are pathogenic in vivo. Blood 2004; 104:1411-1418.
94. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317-1330.
95. Munoz LE, Gaipl US, Franz S, et al. SLE: a disease of clearance deficiency? Rheumatology (Oxford) 2005; 44:1101-1107.
96. Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010; 107:9813-9818.
97. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981; 1:55-60.
98. Puccetti A, Madaio MP, Bellese G, Migliorini P. AntiDNA antibodies bind to dnase I. J Exp Med 1995; 181:1797-1804.
99. Yeh TM, Chang HC, Liang CC, et al. Deoxyribonuclease-inhibitory antibodies in systemic lupus erythematosus. J Biomed Sci 2003; 10:544-551.
100. Martinez-Valle F, Balada E, Ordi-Ros J, et al. Dnase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 2009; 18:418-423.
101. Guiducci C, Tripodo C, Gong M, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010; 207:2931-2942.
102. Midgley A, Mayer K, Edwards SW, Beresford MW. Differential expression of factors involved in the intrinsic and extrinsic apoptotic pathways in juvenile systemic lupus erythematosus. Lupus 2011; 20:71-79.
103. Midgley A, McLaren Z, Moots RJ, et al. The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2390-2401.
104. Midgley A, Beresford MW. Cellular localization of nuclear antigen during neutrophil apoptosis: mechanism for autoantigen exposure? Lupus 2011; 20:641-646.
105. Decker P, Singh-Jasuja H, Haager S, et al. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a myd88-independent pathway: consequences on inflammation. J Immunol 2005; 174:3326-3334.
106. Decker P, Wolburg H, Rammensee HG. Nucleosomes induce lymphocyte necrosis. Eur J Immunol 2003; 33:1978-1987.
107. Lindau D, Ronnefarth V, Erbacher A, et al. Nucleosome-induced neutrophil activation occurs independently of tlr9 and endosomal acidification: implications for systemic lupus erythematosus. Eur J Immunol 2011; 41:669-681.
108. Patel S, Kumar S, Jyoti A, et al. Nitric oxide donors release extracellular traps from human neutrophils by augmenting free radical generation. Nitric Oxide 2010; 22:226-234.
109. Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Panomvana Na Ayudhya D. The effect of high dose of n-acetylcysteine in lupus nephritis: a case report and literature review. J Clin Pharm Ther 2010; 35:483-485.
110. Frese S, Diamond B. Structural modification of DNA: a therapeutic option in SLE? Nat Rev Rheumatol 2011; 7:733-738.
111. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ betainducible genes and downstream effect in a phase i trial of an antiinterferonalpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1785-1796.
112. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186:4794-4804.
113. Tillack K, Breiden P, Martin R, Sospedra M. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol 2012; 188:3150-3159.
114. Puga I, Cols M, Barra CM, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 2012; 13:170-180.